Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease

(2011) A Tsuboi et al.   LEUKEMIA

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

(2010) P. G. Maslak et al.   BLOOD

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909

(2010) Jürgen Kuball et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies

(2010) K. Rezvani et al.   HAEMATOLOGICA

Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

(2010) Y. Saito et al.   Science Translational Medicine

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

(2009) U. Keilholz et al.   BLOOD

IL15 Can Reverse the Unresponsiveness of Wilms' Tumor Antigen-Specific CTL in Patients with Prostate Cancer

(2009) J. W. King et al.   CLINICAL CANCER RESEARCH

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

Phenotype and Functional Characterization of Long-term gp100-Specific Memory CD8+ T Cells in Disease-Free Melanoma Patients Before and After Boosting Immunization

(2008) E. B. Walker et al.   CLINICAL CANCER RESEARCH

Avidity maturation of memory CD8 T cells is limited by self-antigen expression

(2008) Michael J. Turner et al.   JOURNAL OF EXPERIMENTAL MEDICINE